Fundraising FoxOberland Capital
Venture debtNew York · Growth–Late Stage · 20 people tracked
Also known as OBERLAND CAPITAL MANAGEMENT LLC
Find your way into Oberland Capital
Sign up to see every warm intro you have to Oberland Capital
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Oberland Capital team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Oberland Capital focuses on funding innovation across the global healthcare industry through flexible, customized investment structures. Its financing solutions include the monetization of royalty streams, acquisition of future product revenues, creation of project-based financing structures, and investments in traditional debt and equity. The firm aims to accelerate the development and commercialization of promising healthcare products to create value for partners and transform patient care.
Source: firm website, verified Sep 29, 2026.
Team · 20 people
from the firm's website
What they invest in
from 18 of 19 portfolio companiesBiotech ×17Healthtech ×13Medical Devices ×13Deep Tech ×5Digital Health ×4Advanced Manufacturing ×1
HQs:United States×15Switzerland×1United Kingdom×1
Investments · 19 tracked
founders shown can be your intro pathMeira GTx develops genetic medicine treatments for patients with devastating diseases, leveraging expertise in drug development and manufacturing.
BiotechDeep TechHealthtechMedical Devices
Alexandria Forbes(President and Chief Executive Officer and Director)Richard Giroux(Chief Operating Officer and Chief Financial Officer)Stuart Naylor(Chief Development Officer)Robert K. Zeldin(Chief Medical Officer)
Co-investorsAlbionVCUCL Technology Fund
Agenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL.
BiotechHealthtechLexington, US
Garo Armen(Chairman & CEO, Co-founder)Ozer Baysal(Executive Officer)Robert Stein(Executive Officer)Christine Klaskin(Executive Officer)inKaren Valentine(Executive Officer)Steven O'Day(Chief Medical Officer)in
Co-investorsAdvent Life SciencesGrazia Equity GmbHHEALTHCARE ROYALTY PARTNERSCommodore CapitalInvusLigand Pharmaceuticals+1 more
BillionToOne is a precision diagnostics company that uses molecular counting technology to develop non-invasive prenatal screening and liquid biopsy tests for early disease detection.
BiotechDigital HealthHealthtechMedical DevicesSan Francisco, US
Oguzhan Atay(Founder)inDavid Tsao(CTO)inSukrit Silas(Founder)inBrett Huff(Director of Engineering)Mihir Sewak(Software Engineering Manager)Jen Katzburg(Principal Recruiter)
Co-investors500 Emerging Europe500 GlobalAsymmetry VenturesCivilization Ventures Management, Llce2vcFifty Years+23 more
Biohaven is a pharmaceutical company that discovers, develops, and commercializes medications for neurological and neuropsychiatric diseases, including epilepsy, pain, mood disorders, OCD, spinocerebellar ataxia, and spinal muscular atrophy.
BiotechHealthtechMedical DevicesConnecticut, US
Vlad Coric, M.D.(Chairman & Chief Executive Officer)in
Co-investorsConnecticut InnovationsRA CapitalSixth StreetBlackRock
ClearPoint Neuro develops neurosurgical guidance systems and platforms that enable precise navigation to the brain and spine for device, cell, and gene therapy procedures.
BiotechDeep TechDigital HealthHealthtechMedical DevicesSolana Beach, US
Danilo D'Alessandro(Executive Officer)inMazin Sabra(Executive Officer)inJeremy L. Stigall(Executive Officer)inJoseph M. Burnett(Executive Officer, Director)Jenkins L. Kimble(Executive Officer, Director)Robert C. Korn(Vice President, Sales)
Humacyte is a regenerative medicine company that develops a bioengineered, human-derived Acellular Tissue Engineered Vessel (ATEV) along with a scalable cell sourcing and manufacturing platform.
BiotechHealthtechMedical DevicesMorrisville, US
Laura Niklason, MD, PhD(Founder)inTed Lithgow(Executive Officer)inPaul Boyer(Executive Officer)inCarrie S. Cox(Executive Officer, Director)Dale A. Sander(Chief Financial Officer, Chief Corporate Development Officer and Treasurer)inShamik J. Parikh(Chief Medical Officer)in
Co-investorsFirst In VenturesFresenius Medical Care Ventures
Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing therapies for inherited retinal diseases (IRDs) and other retinal and refractive disorders.
BiotechDeep TechDigital HealthHealthtechMedical DevicesRaleigh, US
Bernhard Hoffmann(Executive Officer)Nirav Jhaveri(Executive Officer)inAmy Rabourn(Executive Officer)inGeorge Magrath(Chief Executive Officer)inBen Yerxa(President)inRobert Gagnon(Chief Financial Officer)
Co-investorsMichigan Capital Network
Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients.
BiotechMedical DevicesNeedham, US
Robert WeinbergRICHARD ALDRICH(Director)AMY C. CAVERS(Executive Officer)inCATHY CAREW(Executive Officer)inJONATHAN PACHTER(Executive Officer)inROB GAGNON(Executive Officer)in
Co-investorsBessemer Venture PartnersCardinal PartnersForesite CapitalLightstone VenturesLongwood FundViking Global+1 more
BiotechMiramar, US
Hing C Wong(Executive Officer, Director)Peter Rhode(Executive Officer)
BoardAdam Waldman(Director)Fred Middleton(Director)C. Boyder Gray(Director)
Co-investorsNew World AngelsSanderling Ventures
Axogen develops surgical technologies and solutions for peripheral nerve repair procedures across various anatomical locations.
HealthtechMedical Devices
Michael Dale(President, Chief Executive Officer and Board Director)in
BoardPaul G. Thomas(Chairman of the Board)Amy Wendell(Director)William Burke(Director)John H. Johnson(Director)Alan M. Levine(Director)
Centessa is a biopharmaceutical company developing an Orexin Receptor 2 Agonist program aimed at treating sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders.
BiotechHealthtech
Co-investorsAdvent Life SciencesEcoR1 CapitalForesite CapitalLifeSci Venture PartnersMedicxiScion Life Sciences+4 more
Biopharma developing HDL-C regulating therapies; listed 2000.
BiotechAnn Arbor, US
Roger S. Newton(Director)inTim M. Mayleben(Executive Officer, Director)
BoardDaniel Janney(Director)Dov A. Goldstein(Director)Nicole Vitullo(Director)inPatrick Enright(Director)in
Co-investorsAisling CapitalAlta PartnersArboretum VenturesARCHIMED JapanAsset Management CompanyCanaan Partners+3 more
Invitae provides genetic testing services to patients and clinicians across the United States, offering broad test offerings and genetic counseling to inform health decisions at every stage of life.
BiotechDigital HealthHealthtechMedical DevicesSan Francisco, US
Sean George(Executive Officer, Director)inRandal Scott(Executive Officer, Director)Shelly Guyer(Executive Officer)inLee Bendekgey(Executive Officer)inGeoffrey Crouse(Director)
BoardEric Aguiar(Director)in
Co-investorsCivilization Ventures Management, LlcDecheng CapitalFifty YearsManta Ray VenturesPrefix CapitalTech Wildcatters+4 more
Acquired by Shire in 2014 (now part of Takeda).
BiotechMedical Devices
Co-investorsFrazier Life SciencesLongitude CapitalPappas CapitalRiverVest Venture PartnersSanofi Ventures
NorthStar Medical Technologies develops and commercializes innovative nuclear medicine products and technologies for the pharmaceutical and life sciences industries.
BiotechDeep TechMedical DevicesBeloit, US
Oxford Biomedica is a biopharmaceutical contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, lentiviral vector technologies, and bioprocessing solutions.
Advanced ManufacturingBiotechDeep TechHealthtechMedical DevicesOxford, GB
Dr. Frank Mathias(Chief Executive Officer)inDr. Lucinda Crabtree(Chief Financial Officer)
BoardDr. Roch Doliveux(Non-Executive Chair)
Co-investorsNovo Holdings
Primmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy.
BiotechHealthtechCarlsbad, US
James Appleman(SVP, R&D and CSO, Cofounder)Paulo Rangel(Chief Business Officer and Cofounder)inStephen Webber(Vice President, Medicinal Chemistry, and Cofounder)inCharles McDermott(President & CEO, Director)
BoardTodd J Harris(Director)in
Co-investorsBioBritBioRock VenturesSamsara BioCapitalBioqube VenturesPolaris Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Zealand Pharma
Exits · 9
8 IPOs · 1 acquisitions21 MeiraGTxNASDAQ: MGTXAgenusNASDAQ: AGENBillionToOneNASDAQ: BLLNBiohavenNYSE: BHVNClearPoint NeuroNASDAQ: CLPTHumacyteNASDAQ: HUMAOpus GeneticsNASDAQ: IRDVerastemNASDAQ: VSTMLumena Pharmaceuticalsacq. by Shire
Portfolio news
latest coverage across their companies
Agenus · simplywall.st · Aug 15, 2026
Esperion Therapeutics · stocktitan.net · Jun 8, 2026
Primmune Therapeutics · globenewswire.com · Jan 26, 2026
Fund performance · per public LP disclosures · 3
as of Dec 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Oberland Capital Healthcare III LPLPs: Texas Municipal Retirement System | — | — | 2.9% | 1.11x | 0.19x |
| Oberland Capital Healthcare Solutions Co-Invest LPLPs: Texas Municipal Retirement System | — | — | 23.5% | 1.35x | 0.56x |
| Oberland Capital Healthcare Solutions LPLPs: Texas Municipal Retirement System | — | — | 10.6% | 1.22x | 0.58x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- How many investments has Oberland Capital made?
- Oberland Capital has 19 tracked investments, 9 of which have exited.
- What stage does Oberland Capital invest at?
- Oberland Capital invests at the Growth, Late Stage stages.
- What sectors does Oberland Capital focus on?
- Oberland Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Oberland Capital located?
- Oberland Capital is headquartered in New York, US.
- Who does Oberland Capital co-invest with?
- Oberland Capital most often shares deals with Advent Life Sciences, Civilization Ventures Management, Llc, Fifty Years, among 66 tracked co-investors.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Menlo Ventures is an early-stage venture capital firm backing transformative technology companies, with a strong current emphasis on artificial intelligence across enterprise, healthcare, and consumer markets.
Norwest is a venture capital and growth equity investment firm that has backed over 700 companies across technology, consumer, and healthcare over its 65-year history.
5AM Ventures is a life science venture capital firm founded in 2002 that funds and builds next-generation life sciences companies, focusing on biopharmaceuticals, drug delivery technologies, and life science instruments.